Amylin awaits boardroom battle
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals is edging towards a three-way boardroom battle after dissident shareholders filed proposals to elect their supporters to the firm's board. Eastbourne Capital Management and Carl Icahn each nominated five candidates for election, who would compete with Amylin's choices.